Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles
- PMID: 29104700
- PMCID: PMC5658477
- DOI: 10.1186/s12645-017-0030-4
Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles
Abstract
Chemotherapeutic agents have limited efficacy and resistance to them limits today and will limit tomorrow our capabilities of cure. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours. In front of this, multimodality has appeared as a promising strategy to overcome resistance. In this context, the use of nanoparticle-based platforms enables many possibilities to address cancer resistance mechanisms. Nanoparticles can act as carriers and substrates for different ligands and biologically active molecules, antennas for imaging, thermal and radiotherapy and, at the same time, they can be effectors by themselves. This enables their use in multimodal therapies to overcome the wall of resistance where conventional medicine crash as ageing of the population advance. In this work, we review the cancer resistance mechanisms and the advantages of inorganic nanomaterials to enable multimodality against them. In addition, we comment on the need of a profound understanding of what happens to the nanoparticle-based platforms in the biological environment for those possibilities to become a reality.
Keywords: Cancer resistance; Inorganic nanoparticles; Multifunctional; Multimodality; Resistance to treatment.
Figures
References
-
- Alivisatos AP. Less is more in medicine—sophisticated forms of nanotechnology will find some of their first real-world applications in biomedical research, disease diagnosis and possibly, therapy. Sci Am. 2001;285:66–73. doi: 10.1038/scientificamerican0901-66. - DOI
-
- Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–1059. doi: 10.1038/nm1622. - DOI - PubMed
-
- Auzel FE. Materials and devices using double-pumped phosphors with energy transfer. Proc IEEE. 1973;61(6):758–785. doi: 10.1109/PROC.1973.9155. - DOI
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources